Echocardiography-guided radiofrequency ablation for cardiac tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of echocardiography-guided percutaneous radiofrequency ablation, known as the Liwen procedure, for treating cardiac tumors. It is a single-arm, prospective study conducted at Xijing Hospital, where patients with symptomatic cardiac tumors that cannot be surgically removed will receive the Liwen procedure. Participants will be monitored through follow-up assessments at various intervals to evaluate outcomes and safety. The study aims to provide an alternative treatment option for patients who are not candidates for traditional surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Hemodynamic changes caused by cardiac tumors or patients with obvious clinical symptoms such as chest tightness, shortness of breath, palpitations, etc., or the risk of embolization of intracardial tumors;
2. Patients who cannot be completely excised by surgery, cannot tolerate surgery or refuse surgery;
3. The patient was informed of the nature of the clinical study and agreed to participate in all the requirements of the clinical study, signed the informed consent, and agreed to complete the follow-up and follow-up examination required.

Exclusion Criteria:

1. Previously documented persistent ventricular tachycardia or ventricular fibrillation, supraventricular tachycardia with hemodynamic disturbance, cardiac arrest, and high atrioventricular block;
2. Previous history of tumor or thromboembolism exfoliating organ embolism;
3. Combined with other heart diseases requiring surgical treatment;
4. Active infections should be treated with antibiotics;
5. Bleeding constitution and coagulation disorders, or anticoagulation, antiplatelet therapy contraindications;
6. Patients who are pregnant, breastfeeding or planning to become pregnant during the clinical study;
7. The disease will cause difficulties in the evaluation of treatment, such as mental illness, metabolic disease, etc.;
8. Patients who cannot tolerate general anesthesia;
9. Severe liver, kidney, lung, brain and other major organ failure;
10. There are no patients who are suitable for the injection path of Liwen operation;
11. Other diseases deemed unsuitable for inclusion by the researchers;
12. The researcher judged that the patients' dependence was poor and could not complete the study.

Where it's running

• Xijing Hospital
  Xi'an, Shannxi, China Recruiting

Study contacts

• Study coordinator: Liwen Liu
• Email: liuliwen1969@fmmu.edu.cn
• Phone: +86 029 8477 1623

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prognosis prediction for patients with cardiovascular and cerebrovascular diseases using multi-omics

  This study is trying to find out how different biological factors affect people with heart and brain blood vessel diseases to help doctors predict outcomes and personalize treatments for them.

  Recruiting First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shaanxi · NCT06001073

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.